MVA-VLP Platform To Design 2019-nCoV Vaccine Candidates
A Georgia based biotechnology company, GeoVax Labs, Inc., announced the signing of a Letter of Intent (LOI) to jointly develop a vaccine against the new coronavirus known as 2019-nCoV.
Under this LOI collaboration, GeoVax and BravoVax, a vaccine developer in China, will use the MVA-VLP vaccine platform and expertise to design and construct the vaccine candidate using genetic sequences from the ongoing coronavirus outbreak originating in China.
BravoVax will provide further development, including testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities.
For additional 2019-nCoV vaccine news, please visit these links:
Coronavirus news published by Coronavirus Today.
Our Trust Standards: Medical Advisory Committee
-
Fact checked by Danielle Reiter, RN
-
Fact checked by Robert Carlson, MD